Advertisement

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

First International Summit on Interventional Pharmacoeconomics

Advertisement

Related Videos

David A. Hyman, MD, JD, on Inclusive Shared Savings

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Advertisement

Advertisement

Aug

14

Today In Oncology

TOPAZ-1 Post Hoc Analysis Supports Durvalumab Plus Chemotherapy in Advanced Biliary Tract Cancer

Advanced Gastric or GEJ Cancer First-Line Disitamab Vedotin, Tislelizumab, and S-1

Proton Pump Inhibitor, Antibiotic Exposure Linked to Inferior Durvalumab Outcomes in Unresectable Stage III NSCLC

Does ctDNA-Guided Surveillance After Curative-Intent Surgery Benefit Outcomes in Cases of Recurrent Colorectal Cancer

Darolutamide Plus Goserelin in AR-Positive Salivary Gland Carcinoma

Advertisement

© 2026 HSP News Service, L.L.C.